Therefore, we evaluated whether selective targeting of MKK7 using anti-sense oligonucleotides (ASOs) would block arthritis-associated JNK activation and decreased arthritis severity in K/BxN serum transfer arthritis. The gene discussed is MAP2K7; the disease is Arthritis.